Disease on EC 3.1.1.28 - acylcarnitine hydrolase
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE 
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma.
Breast Neoplasms
Effect of interferon-?2b on the expression of various drug-metabolizing enzymes and transporters in co-cultures of freshly prepared human primary hepatocytes.
Carcinoma
Visualization of carboxylesterase 2 with a near-infrared two-photon fluorescent probe and potential evaluation of its anticancer drug effects in an orthotopic colon carcinoma mice model.
Chemical and Drug Induced Liver Injury
Endoplasmic Reticulum Targeting Ratiometric Fluorescent Probe for Carboxylesterase 2 Detection in Drug-Induced Acute Liver Injury.
Colonic Neoplasms
Carboxylesterase 2 production and characterization in human cells: new insights into enzyme oligomerization and activity.
Colorectal Neoplasms
A highly selective near infrared fluorescent probe for carboxylesterase 2 and its biological applications.
Colorectal Neoplasms
Carboxylesterase 2 is downregulated in colorectal cancer following progression of the disease.
Colorectal Neoplasms
Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer.
Colorectal Neoplasms
High-throughput proteomics integrated with gene microarray for discovery of colorectal cancer potential biomarkers.
Colorectal Neoplasms
Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38.
Colorectal Neoplasms
The Relationship between TP53 Gene Status and Carboxylesterase 2 Expression in Human Colorectal Cancer.
Fatty Liver
Carboxylesterase 2 prevents liver steatosis by modulating lipolysis, ER stress and lipogenesis and is regulated by HNF4?.
Glioma
Carboxylesterase 2 production and characterization in human cells: new insights into enzyme oligomerization and activity.
Hypertension
Carboxylesterase 2 and Intestine Transporters Contribute to the Low Bioavailability of Allisartan, a Prodrug of Exp3174 for Hypertension Treatment in Humans.
Liver Diseases
Intestine-Specific Overexpression of Carboxylesterase 2c Protects Mice From Diet-Induced Liver Steatosis and Obesity.
Metabolic Diseases
Carboxylesterase 2 proteins are efficient diglyceride and monoglyceride lipases possibly implicated in metabolic disease.
Neoplasms
Carboxylesterase 2 is downregulated in colorectal cancer following progression of the disease.
Neoplasms
Efficacy and Safety of CAP7.1 as Second-Line Treatment for Advanced Biliary Tract Cancers: Data from a Randomised Phase II Study.
Neoplasms
Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts.
Neoplasms
Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer.
Neoplasms
Tissue-infiltrating plasma cells are an important source of carboxylesterase 2 contributing to the therapeutic efficacy of prodrugs.
Non-alcoholic Fatty Liver Disease
Intestine-Specific Overexpression of Carboxylesterase 2c Protects Mice From Diet-Induced Liver Steatosis and Obesity.
Obesity
Human Carboxylesterase 2 Reverses Obesity-Induced Diacylglycerol Accumulation and Glucose Intolerance.
Pulmonary Disease, Chronic Obstructive
Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients.
Thyroid Neoplasms
Preclinical Efficacy of a Carboxylesterase 2-Activated Prodrug of Doxazolidine.
Vaccinia
Characterization of Oncolytic Vaccinia Virus Harboring the Human IFNB1 and CES2 Transgenes.
html completed
